|
Name |
12β,15α,25,28-tetrahydroxyergosta-4,6,8(14),22-tetraen-3-one
|
Molecular Formula | C28H40O5 | |
IUPAC Name* |
12,15-dihydroxy-17-[6-hydroxy-5-(hydroxymethyl)-6-methylhept-3-en-2-yl]-10,13-dimethyl-1,2,9,11,12,15,16,17-octahydrocyclopenta[a]phenanthren-3-one
|
|
SMILES |
CC(C=CC(CO)C(C)(C)O)C1CC(O)C2=C3C=CC4=CC(=O)CCC4(C)C3CC(O)C21C
|
|
InChI |
InChI=1S/C28H40O5/c1-16(6-7-18(15-29)26(2,3)33)21-13-23(31)25-20-9-8-17-12-19(30)10-11-27(17,4)22(20)14-24(32)28(21,25)5/h6-9,12,16,18,21-24,29,31-33H,10-11,13-15H2,1-5H3/b7-6+/t16-,18-,21-,22+,23+,24-,27+,28+/m1/s1
|
|
InChIKey |
XJROYMDLDCJXJR-VPIWMDLGSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 456.62 | ALogp: | 3.5 |
HBD: | 4 | HBA: | 5 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 98.0 | Aromatic Rings: | 4 |
Heavy Atoms: | 33 | QED Weighted: | 0.464 |
Caco-2 Permeability: | -4.786 | MDCK Permeability: | 0.00001940 |
Pgp-inhibitor: | 0.978 | Pgp-substrate: | 0.091 |
Human Intestinal Absorption (HIA): | 0.647 | 20% Bioavailability (F20%): | 0.004 |
30% Bioavailability (F30%): | 0.005 |
Blood-Brain-Barrier Penetration (BBB): | 0.988 | Plasma Protein Binding (PPB): | 91.95% |
Volume Distribution (VD): | 1.21 | Fu: | 5.37% |
CYP1A2-inhibitor: | 0.005 | CYP1A2-substrate: | 0.118 |
CYP2C19-inhibitor: | 0.012 | CYP2C19-substrate: | 0.863 |
CYP2C9-inhibitor: | 0.013 | CYP2C9-substrate: | 0.194 |
CYP2D6-inhibitor: | 0.002 | CYP2D6-substrate: | 0.138 |
CYP3A4-inhibitor: | 0.291 | CYP3A4-substrate: | 0.732 |
Clearance (CL): | 6.982 | Half-life (T1/2): | 0.315 |
hERG Blockers: | 0.044 | Human Hepatotoxicity (H-HT): | 0.023 |
Drug-inuced Liver Injury (DILI): | 0.042 | AMES Toxicity: | 0.017 |
Rat Oral Acute Toxicity: | 0.25 | Maximum Recommended Daily Dose: | 0.93 |
Skin Sensitization: | 0.111 | Carcinogencity: | 0.728 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.008 |
Respiratory Toxicity: | 0.871 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004366 | 0.842 | D0N1TP | 0.326 | ||||
ENC004997 | 0.824 | D0F1UL | 0.286 | ||||
ENC004998 | 0.642 | D0G5CF | 0.286 | ||||
ENC003739 | 0.527 | D0T2PL | 0.276 | ||||
ENC003880 | 0.474 | D05BTM | 0.276 | ||||
ENC003368 | 0.458 | D01QUS | 0.265 | ||||
ENC004737 | 0.457 | D0Y2YP | 0.263 | ||||
ENC004022 | 0.457 | D03BLF | 0.262 | ||||
ENC001861 | 0.457 | D0KR5B | 0.260 | ||||
ENC004834 | 0.437 | D02ZGI | 0.257 |